Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD)
Kenneth Blum, Abdalla Bowirrat, Baron D, Lisa Lott, Jessica V. Ponce, Raymond Brewer, David Siwicki, Brent Boyett, Gondre-Lewis MC, Smith De, Panayotis K. Thanos, Sampada Badgaiyan, Mary Hauser, L. P. Fried, Akash Roy, Downs BW, Badgaiyan RD
Abstract
controls derived from the current literature. We strongly suggest that while we may take argument concerning many of these so-called controls (e.g. blood donors) it is quite remarkable that there are a plethora of case -control studies indicating selective association of these risk alleles ( measured in GARS) for the most part indicating a hypodopaminergia. The paper presents the detailed methodology of the GARS. Data collection procedures, instrumentation, and the analytical approach used to obtain GARS and subsequent research objectives are described. Can we combat SUD through early genetic risk screening in the addiction field enabling early intervention by the induction of dopamine homeostasis? It is envisaged that GARS type of screening will provide a novel opportunity to help identify causal pathways and associated mechanisms of genetic factors, psychological characteristics, and addictions awaiting additional scientific evidence including a future meta- analysis of all available data -a work in progress.